Read Gene

Read Gene EBITDA Margin

The EBITDA Margin of Read Gene (RDG.WA) as of Nov 5, 2026 is 5.15 %. In the previous year, EBITDA Margin was 0.69 % — a change of 644.02% (higher).

EBITDA Margin

5.15 %

YoY

644.02%

Last updated:

EBITDA Margin of Read Gene is 2025 5.15 % . EBITDA Margin of Read Gene was 2024 0.69 % . It decreases by 644.02% higher compared to the previous year.

The Read Gene EBITDA Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Margin
Date
EBITDA Margin
Jan 1, 2018
48.95 PLN
Jan 1, 2019
33.65 PLN
Jan 1, 2020
25.43 PLN
Jan 1, 2021
10.44 PLN
Jan 1, 2022
10.25 PLN
Jan 1, 2023
-7.68 PLN
Jan 1, 2024
0.69 PLN
Jan 1, 2025
5.15 PLN
The Read Gene EBITDA Margin history
YEAREBITDA MarginYoY
5.15 %+644.02%
0.69 %-109.01%
-7.68 %-174.97%
10.25 %-1.77%
10.44 %-58.96%
25.43 %-24.44%
33.65 %-31.25%
48.95 %-4.95%
51.50 %+172.01%
18.93 %-62.63%
50.67 %-454.66%
-14.29 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Read Gene Stock analysis

What does Read Gene do? Read Gene SA generates revenue through medical research and testing services, focusing on malignant tumor detection, prevention, and treatment. The company offers breast cancer, colon cancer, and prostate cancer tests, along with medical consultancy, DNA tests, and supplements. Its subsidiary Dieta Antyrakowa Read-Gene Sp. z o.o. supports these services, while major shareholder GEN-PAT-MED Sp. z o.o. provides strategic backing. Clients include patients seeking cancer diagnostics and preventive care, as well as healthcare providers integrating these tests into treatment protocols. The firm's chemoprevention, clinical trials, and genetic testing specialties drive product sales to hospitals, clinics, and individual consumers. Breast cancer, colon cancer, and prostate cancer tests are key revenue streams, complemented by DNA tests and supplements. Medical consultancy services cater to institutions requiring expert guidance on cancer-related health strategies. Read Gene SA's product portfolio is structured around three core fields: chemoprevention, clinical trials, and genetic testing. The company monetizes genetic testing services, particularly for breast, colon, and prostate cancers, alongside DNA tests and supplements. Healthcare institutions and private clients form the primary customer segments, with Dieta Antyrakowa Read-Gene Sp. z o.o. serving as the operational arm for these offerings. Read Gene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Read Gene stock

EBITDA Margin of Read Gene is 5.15 % in 2025.

EBITDA Margin of Read Gene changed from 0.69 % to 5.15 %, representing a 644.02% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA Margin Read Gene since 2006 – with annual values, charts, and detailed analysis.

EBITDA Margin shows what percentage of revenue converts to EBITDA. It normalizes for depreciation and capital structure differences.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBITDA Margin's Read Gene with sector peers and the industry average to assess whether it is attractive.

To evaluate EBITDA Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBITDA Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Read Gene

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Read Gene